How Pharmaceutical Companies Use EPCG Scheme to Reduce Capital Costs

4 Views

The pharmaceutical industry is one of the largest beneficiaries of India’s Export Promotion Capital Goods (EPCG) Scheme. With pharmaceutical manufacturing heavily dependent on advanced machinery, cleanroom systems, testing equipment, and automation technologies, capital investment requirements are extremely high. The EPCG Scheme helps pharma companies significantly reduce these costs by allowing duty-free import of capital goods against export obligations.

For pharmaceutical manufacturers focused on exports, EPCG provides a strategic advantage by lowering upfront machinery expenses while supporting technology modernization and global compliance standards.

This article explains how pharmaceutical companies use the EPCG Scheme to reduce capital costs, improve manufacturing capability, and enhance export competitiveness.

What Is the EPCG Scheme?

The Export Promotion Capital Goods (EPCG) Scheme is a government initiative under India’s Foreign Trade Policy (FTP) that allows businesses to import capital goods at zero customs duty, subject to fulfillment of export obligations within a specified period.

The scheme is administered by the Directorate General of Foreign Trade (DGFT) and is widely used by export-oriented industries, including pharmaceuticals, chemicals, engineering, textiles, and food processing.

Under EPCG, companies can import:

Manufacturing machinery
Production equipment
Testing and laboratory instruments
Packaging systems
Automation technology
Quality control equipment
Spare parts and accessories

without paying full import duties.

Why Pharmaceutical Companies Require High Capital Investment

Pharmaceutical manufacturing is highly regulated and technology-intensive. To comply with international standards such as WHO-GMP, US FDA, EU GMP, and MHRA requirements, companies must invest heavily in modern infrastructure and specialized machinery.

Common high-cost pharmaceutical equipment includes:

Tablet compression machines
Capsule filling machines
Sterile manufacturing systems
Cleanroom equipment
Fluid bed dryers
Granulation systems
Lyophilizers
Blister packaging machines
HVAC systems
Laboratory testing instruments
Automated inspection systems

Many of these machines are imported from countries such as Germany, Italy, Switzerland, Japan, and the United States, making import duties a major cost factor.

How EPCG Helps Pharmaceutical Companies Reduce Capital Costs

1. Duty-Free Import of Pharmaceutical Machinery

The biggest advantage of EPCG is the exemption from customs duties on imported capital goods.

Without EPCG, importing pharmaceutical equipment may involve:

Basic Customs Duty (BCD)
Additional duties
IGST and related import charges in certain cases

Under EPCG, eligible companies can substantially reduce or eliminate these duty costs.

For large pharmaceutical projects, this can save crores of rupees in initial capital expenditure.

2. Lower Production Setup Costs

New pharmaceutical plants require major investment in:

Manufacturing lines
Validation systems
Packaging units
Testing laboratories
Sterile production environments

By reducing machinery import costs, EPCG lowers the total project setup cost and improves return on investment.

This is especially beneficial for:

Bulk drug manufacturers
API manufacturers
Formulation companies
Injectable manufacturers
Nutraceutical exporters
Contract manufacturing companies

3. Technology Upgradation at Reduced Cost

Global pharmaceutical buyers demand strict quality standards and advanced manufacturing capabilities.

The EPCG Scheme encourages pharma companies to upgrade technology by making imported high-end equipment more affordable.

This allows businesses to invest in:

Automated production systems
Precision manufacturing equipment
Digital quality monitoring systems
High-speed packaging lines
AI-enabled inspection systems

Technology modernization also improves operational efficiency and reduces wastage.

4. Improved Export Competitiveness

Indian pharmaceutical companies export medicines to highly regulated international markets.

Lower capital costs help manufacturers:

Reduce production costs
Improve product pricing
Increase profit margins
Expand export capacity
Compete globally

This strengthens India’s position as one of the world’s largest pharmaceutical exporters.

5. Expansion Into Regulated Markets

Markets such as the United States, Europe, Australia, and Japan require advanced manufacturing infrastructure and compliance systems.

EPCG enables pharma companies to invest in internationally compliant equipment while minimizing import-related financial burden.

This supports certifications such as:

US FDA approval
EU GMP certification
WHO GMP compliance
MHRA approval

Types of Pharmaceutical Equipment Eligible Under EPCG

Pharmaceutical companies commonly import the following machinery under EPCG:

Manufacturing Equipment

Tablet manufacturing machines
Capsule filling systems
Coating machines
Mixing and blending equipment
Reactors and fermenters

Packaging Machinery

Blister packaging machines
Bottle filling systems
Labeling machines
Cartoning systems

Laboratory & Testing Equipment

HPLC systems
Spectrophotometers
Stability chambers
Dissolution testing systems

Utility & Support Systems

HVAC systems
Purified water systems
Sterile cleanroom equipment
Air handling units

Export Obligation Under EPCG

To avail EPCG benefits, pharmaceutical companies must fulfill export obligations within the prescribed time period.

Typically, export obligation is calculated as:

EO=6×Duty Saved Amount

The export obligation period is generally six years.

Exports can include:

Finished pharmaceutical products
APIs (Active Pharmaceutical Ingredients)
Bulk drugs
Nutraceuticals
Healthcare products

Companies must maintain proper export documentation and comply with DGFT requirements.

Compliance Requirements for Pharma Companies

While EPCG offers major financial benefits, compliance is critical.

Pharmaceutical companies must ensure:

Proper EPCG authorization before import
Installation of imported machinery
Submission of installation certificate
Accurate export documentation
Fulfillment of export obligation
Timely filing with DGFT
Maintenance of records for audits

Failure to comply may lead to:

Recovery of duty benefits
Interest liabilities
Penalties
Authorization cancellation

Common Challenges Faced by Pharmaceutical Companies

Complex Documentation

EPCG applications require detailed technical and financial documentation related to machinery imports and export capability.

Export Obligation Pressure

Companies must carefully monitor exports to ensure obligations are fulfilled within the allowed period.

Regulatory Coordination

Pharma companies often need coordination between:

DGFT
Customs
Chartered Engineers
Compliance consultants
Export departments

Delayed Machinery Installation

Installation delays may create compliance complications if installation certificates are not submitted on time.

Why Many Pharma Companies Use EPCG Consultants

Due to complex compliance requirements, many pharmaceutical companies work with EPCG consultants for:

Authorization application
Documentation preparation
Customs coordination
Export obligation tracking
EODC closure
DGFT compliance support

Professional guidance helps reduce compliance risks and administrative delays.

Final Thoughts

The EPCG Scheme plays a major role in helping pharmaceutical companies reduce capital costs while upgrading manufacturing capabilities. By enabling duty-free import of advanced machinery, the scheme supports modernization, export growth, and international competitiveness.

For pharma manufacturers investing in production infrastructure, EPCG is not just a customs benefit — it is a strategic tool for long-term business expansion and global market access.

However, businesses must carefully manage compliance, export obligations, and documentation to fully benefit from the scheme without regulatory complications.